When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites Abstract #2870

Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.
Aim(s): Assess the diagnostic value of these 5 neuroendocrine markers across a large series of NEN from multiple origins.
Materials and methods: Expression of ChrA (2 most commonly used clones DAK-A3 and LK2H10), Syn, CD56, ChrB and INSM1 was assessed on 466 NEN (including thymus (11), lung (106), digestive system (301) and Merkel cell carcinomas (48). Pancreatic NEN-look alike were also tested (serous cystadenomas (14), acinar cell carcinomas (21), solid pseudopapillary tumors (31). Markers were defined as positive if expressed by at least 10% of the tumor cells.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Jerome Cros

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2844 Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis
Introduction: Although rectal neuroendocrine tumors (NETs) with L-cell phenotype and small tumor size generally had better clinical behavior, the new 2019 WHO classification classified all rectal NETs are malignant without considering L-cell phenotype and small tumor size. Therefore, identifying biomarkers of rectal NETs is important to stratify the clinical behavior of rectal NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: M.D. Jisup Kim
Authors: Kim J, Kim J Y, Oh E H, Yang D H, ...
#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
Authors: Shah T, Caplin M, Khan M, Houchard A, ...
#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Valentina Andreasi
#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, ...
#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno